Oxford Biomedica plc (LON: OXB)
London
· Delayed Price · Currency is GBP · Price in GBX
425.00
-1.50 (-0.35%)
Dec 23, 2024, 4:35 PM BST
Oxford Biomedica Revenue
Oxford Biomedica had revenue of 50.81M GBP in the half year ending June 30, 2024, a decrease of -20.65%. This brings the company's revenue in the last twelve months to 97.28M, down -18.26% year-over-year. In the year 2023, Oxford Biomedica had annual revenue of 89.54M, down -36.04%.
Revenue (ttm)
97.28M
Revenue Growth
-18.26%
P/S Ratio
4.42
Revenue / Employee
116.65K
Employees
703
Market Cap
451.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89.54M | -50.45M | -36.04% |
Dec 31, 2022 | 139.99M | -2.81M | -1.97% |
Dec 31, 2021 | 142.80M | 55.07M | 62.77% |
Dec 31, 2020 | 87.73M | 23.67M | 36.95% |
Dec 31, 2019 | 64.06M | -2.72M | -4.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 38.20B |
GSK plc | 31.31B |
Haleon plc | 11.24B |
Smith & Nephew plc | 4.46B |
ConvaTec Group PLC | 1.74B |
Hikma Pharmaceuticals PLC | 2.39B |
Oxford Nanopore Technologies plc | 167.75M |
Animalcare Group plc | 76.10M |
Oxford Biomedica News
- 20 days ago - Small Cap Stocks: Oxford Biomedica, Mirriad, United Oil & Gas - The Armchair Trader
- 3 months ago - Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript - GuruFocus
- 3 months ago - Oxford Biomedica plc (OXBDF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Three Quick Facts: Oxford Biomedica, Rightmove, Galliford Try - The Armchair Trader
- 3 months ago - Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO - GlobeNewsWire
- 4 months ago - Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today - GlobeNewsWire
- 5 months ago - Oxford Biomedica announces CFO transition - GlobeNewsWire
- 8 months ago - Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript - Seeking Alpha